医疗器械巨头史赛克（Stryker，股票代码：SYK）周四公布了强劲的2025年第二季度财报，但意外地未能提振投资者信心。尽管业绩超出市场预期，该公司股价在夜盘交易中仍大跌5.66%，引发市场广泛关注。
根据公司发布的财报，史赛克第二季度调整后每股收益为3.13美元，高于分析师平均预期的3.07美元；营收同比增长11.1%至60.2亿美元，同样超过市场预期的59.3亿美元。公司还上调了2025财年全年展望，预计有机净销售增长为9.5%至10.0%，调整后每股收益在13.40美元至13.60美元之间，高于分析师共识的13.36美元。
然而，尽管财报亮眼且上调了全年指引，史赛克的股价却出现大幅下跌。这一反常现象可能反映了投资者对公司未来增长前景的担忧。值得注意的是，在财报发布之前，史赛克股价今年已累计上涨11.2%。这种强劲的股价表现可能增加了投资者对公司业绩的期望，使得即便是超预期的结果也难以推动股价进一步上涨。此外，市场可能还在关注公司的成本控制、利润率变化等因素。在缺乏更多信息的情况下，投资者似乎选择了谨慎态度，导致股价出现回调。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.